On November 20, AKESO fell 4.43% in regular trading, with shares trading at HK$58.25 and turnover reaching HK$83.86 million.
The latest catalyst is that recent market buybacks have not fully offset the overhang from the FDA complete response letter for ivonescimab’s US filing, leaving investors focused on the potential need for an additional clinical trial and the resulting delay to overseas commercialization.
Company disclosures show the trustee bought about 200,000 shares for roughly HK$12 million on November 19, following purchases from November 16 to 18 and a board-approved additional buyback authorization of up to HK$200 million funded by existing cash resources. Management said the purchases reflect confidence in business prospects and valuation, but the market is still reassessing the impact of the US regulatory setback on launch timing and expected returns.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments